These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [BCG therapy. Its role in the treatment of tumors of the bladder]. Patard JJ; Chopin DK; Abbou CC Ann Urol (Paris); 1995; 29(5):292-3. PubMed ID: 8638911 [No Abstract] [Full Text] [Related]
7. [The need of prolonged BCG treatment in superficial bladder cancer is suggested by the development of a peripheral immune response induced by BCG]. Shekarsarai H; Zlotta AR; Drowart A; Van Vooren JP; De Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K Acta Urol Belg; 1997 Mar; 65(1):1-4. PubMed ID: 9245197 [TBL] [Abstract][Full Text] [Related]
8. [The immunotherapy and immunoprophylaxis of bladder cancer]. Figurin KM; Tsiganu VI Urol Nefrol (Mosk); 1993; (4):46-9. PubMed ID: 8310570 [No Abstract] [Full Text] [Related]
10. [The influence over the long-term prognosis of BCG therapy and the surgical treatment in superficial bladder cancer treatment]. Higashi S; Matsui Y; Takahashi T; Nishiyama H; Ito N; Yamamoto S; Kamoto T; Ogawa O Hinyokika Kiyo; 2005 Aug; 51(8):529-31. PubMed ID: 16164268 [TBL] [Abstract][Full Text] [Related]
11. Is intravesical bacillus Calmette-Guérin better than mitomycin for intermediate-risk bladder cancer? Dalbagni G Eur Urol; 2009 Aug; 56(2):257-8; discussion 258-9. PubMed ID: 19427109 [No Abstract] [Full Text] [Related]
12. Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49). Günther JH; Frambach M; Deinert I; Brandau S; Jocham D; Böhle A J Urol; 1999 May; 161(5):1702-6. PubMed ID: 10210443 [TBL] [Abstract][Full Text] [Related]
13. BCG in bladder cancer. Meek D Nurs Times; 1994 Oct 26-Nov 1; 90(43):34-5. PubMed ID: 7984457 [TBL] [Abstract][Full Text] [Related]
14. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder. Pham HT; Soloway MS Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909 [TBL] [Abstract][Full Text] [Related]
15. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. de Reijke TM; de Boer EC; Kurth KH; Schamhart DH J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640 [TBL] [Abstract][Full Text] [Related]
16. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897). Van der Meijden AP; Hall RR; Macaluso MP; Pawinsky A; Sylvester R; Van Glabbeke M Eur Urol; 1996; 29(2):199-203. PubMed ID: 8647147 [TBL] [Abstract][Full Text] [Related]
17. Miliary tuberculosis of the lung in a patient treated with bacillus Calmette-Guerin for superficial bladder cancer. Iantorno R; Nicolai M; Storto ML; Ciccotosto C; Cipollone G; Mastroprimiano G; Tenaglia RL J Urol; 1998 May; 159(5):1639-40. PubMed ID: 9554372 [No Abstract] [Full Text] [Related]
18. [A comparative study of BCG and mitomycin C in superficial carcinomas of the bladder]. Iavarone C; Minocchi L; Arecchi S; Nicolucci D; Porcelli C; D'orazi V; Greco L; Stio F; Martino G; Messinetti S G Chir; 1996 May; 17(5):289-91. PubMed ID: 8755233 [No Abstract] [Full Text] [Related]